Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Revenue readings, the most recent being $214.3 million for Q1 2026.

  • On a quarterly basis, Revenue rose 55.51% to $214.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $754.0 million, a 56.71% increase, with the full-year FY2025 number at $677.6 million, up 60.09% from a year prior.
  • Revenue hit $214.3 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $202.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $214.3 million in Q1 2026 to a low of -$148.3 million in Q4 2022.
  • Median Revenue over the past 5 years was $99.1 million (2022), compared with a mean of $93.8 million.
  • The widest YoY moves for Revenue: up 719.64% in 2022, down 891.12% in 2022.
  • Kiniksa Pharmaceuticals International's Revenue stood at -$148.3 million in 2022, then skyrocketed by 156.24% to $83.4 million in 2023, then soared by 46.93% to $122.5 million in 2024, then skyrocketed by 64.95% to $202.1 million in 2025, then grew by 6.01% to $214.3 million in 2026.
  • The last three reported values for Revenue were $214.3 million (Q1 2026), $202.1 million (Q4 2025), and $180.9 million (Q3 2025) per Business Quant data.